- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00242307
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)
October 31, 2016 updated by: AstraZeneca
A Confirmatory Study of APTA-2217 in Adult Patients With Bronchial Asthma (A Placebo-controlled Double-blind Comparative Study)
The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with asthma.
Roflumilast will be administered orally once daily.
The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks).
The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
Study Overview
Study Type
Interventional
Enrollment (Actual)
450
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Osaka, Japan
- Nycomed Japan and Mitsubishi Tanabe Pharma Corporation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Main inclusion criteria:
- Adult patients with bronchial asthma meeting the Guideline for Prevention and Control of Asthma 2003 (JGL 1998, revised 2nd edition)
- No change in asthma treatment during the last 4 weeks prior to the registration
- Non-smokers or ex-smokers for 12 months or more
- %FEV1 ranging between 60 and 80%
Main exclusion criteria:
- Patients with poorly controlled asthma
- Inhalation therapy exceeding low dose during 4 weeks prior to the registration
- Concurrent respiratory diseases such as COPD considered to affect the efficacy evaluation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
change in lung function parameters.
|
Secondary Outcome Measures
Outcome Measure |
---|
pulmonary function test (spirometry), asthma symptoms, rescue medication, evaluation of QOL, asthma exacerbation, adverse events, pharmacokinetics.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Primary Completion (Actual)
September 1, 2006
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
October 19, 2005
First Submitted That Met QC Criteria
October 19, 2005
First Posted (Estimate)
October 20, 2005
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
October 31, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APTA-2217-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchial Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SamA Pharmaceutical Co., LtdCompleted
-
Johann Wolfgang Goethe University HospitalCompleted
-
AstraZenecaRecruitingBronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)Japan
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Poland, Germany, Ukraine, Czech Republic
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Hungary, Germany, Poland, Bulgaria, Ukraine, Czech Republic
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Johann Wolfgang Goethe University HospitalWithdrawnAllergy | Allergic Asthma | Intrinsic Asthma | Bronchial HyperresponsivenessGermany
Clinical Trials on Roflumilast
-
University of MiamiForest LaboratoriesCompleted
-
Asan Medical CenterUnknownChronic Obstructive Pulmonary DiseaseKorea, Republic of
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis EczemaUnited States, Canada
-
FLUIDDA nvTerminatedPulmonary Disease, Chronic ObstructiveBelgium
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease | COPDUnited States, France, Poland, South Africa, Canada, Germany
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease, COPDFrance, Poland, South Africa, Spain, United States, Canada, United Kingdom
-
AstraZenecaCompletedAsthmaUnited States, Argentina, Colombia, Mexico, Peru
-
Seoul National University Bundang HospitalUnknownSymptomatic BronchiectasisKorea, Republic of
-
AstraZenecaCompletedCOPDSweden, Germany, United States, Norway
-
AstraZenecaCompletedAsthmaUnited States, Russian Federation, Ukraine